LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
Experts in humanising #monoclonalantibodies (mAbs) with 98% success.🧪
We collaborate to bring the most promising c… https://t.co/XX2jr1O1Ns
LifeArc helps create new MRC spin-out company
Our technology transfer team played a crucial role in the formation of Constructive Bio, a new Medical…
Driving translational research into childhood rare diseases
Four grants awarded to projects that aim to translate research discoveries into benefits for children affected by rare diseases
New £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease
Collaboration will work together to find solutions to MND within years, not decades
New £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
Promising new asthma medicine ready to enter early clinical trials
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
LifeArc and Scottish Government work together to drive Scottish research into rare diseases
LifeArc and the Chief Scientist Office (CSO) for the Scottish Government have today jointly awarded a total…
Study reveals gene faults underpinning severe Covid-19
The study paves the way for new tests and treatments to protect people from infection.